10 Biomarkers Every GLP-1 Patient Should Track (And What They Mean)

You are taking one of the most pharmacologically sophisticated metabolic medications developed in the last two decades. The GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and their predecessors — have fundamentally shifted how clinicians think about obesity, insulin resistance, and cardiovascular risk. (For a deeper look at how these medications work alongside lifestyle, see Meto's guide to GLP-1 Medications & Lifestyle: Balancing Medication, Nutrition, and Habits.) And yet, a surprisingly large number of patients on these medications receive little to no systematic guidance on which laboratory markers to monitor, how frequently to test, and what the numbers actually mean.

The 10 Biomarkers at a Glance

For patients who want a quick reference, here are the ten core markers, their primary clinical purpose on GLP-1 therapy, and the direction you should expect them to move with effective treatment and good lifestyle support:

1. HbA1c: Long-term glucose control — should fall with effective GLP-1 therapy
2. Fasting Glucose: Immediate glucose snapshot — self-terminating mechanism reduces hypoglycaemia risk
3. Lipid Panel: Cardiovascular risk — LDL, triglycerides fall; HDL typically rises
4. ALT / AST: Liver safety — improves in NAFLD; monitor for any upward trend
5. eGFR / Creatinine: Kidney safety — benefits in diabetes; monitor hydration vigilantly
6. TSH: Thyroid function — rules out conditions that mimic GLP-1 side effects
7. CBC: Blood health — detects iron deficiency and B12/folate-related anaemia
8. Vitamin B12: Neurological safety — progressive decline risk; supplement proactively
9. Vitamin D & Calcium: Bone health — prevent rapid weight loss-associated bone density loss
10. hsCRP: Systemic inflammation — broad metabolic dividend marker; lifestyle-responsive

GLP-1 therapy, used intelligently, is one of the most meaningful metabolic interventions available to patients managing obesity, insulin resistance, and cardiometabolic risk. The laboratory markers in this guide are not obstacles to treatment — they are the evidence that your treatment is working, the early warning system when it is not, and the data foundation on which personalised clinical decisions should be made. Track them. Understand them. Use them.

For a broader view of the GLP-1 landscape — including a look at the first oral GLP-1 pill to receive FDA approval — see Meto's article on Foundayo (Orforglipron): The First GLP-1 Weight Loss Pill. And to order your comprehensive metabolic panel, visit meto.co/labs.

That gap matters. GLP-1 receptor agonists do not act on a single pathway — they influence glucose metabolism, gastric motility, lipid processing, hepatic fat content, renal function, and appetite regulation simultaneously. That breadth is precisely what makes them powerful. It is also why monitoring a handful of key biomarkers is not a bureaucratic formality. It is the difference between using these medications intelligently and using them blindly.

Introduction

A biomarker, in clinical terms, is a measurable biological indicator — typically a molecule circulating in blood or urine — that reflects the state of a physiological process. Biomarkers can confirm that a treatment is working, detect early signs of organ stress, reveal nutritional deficiencies before they become symptomatic, and guide dose adjustments. For GLP-1 patients, they also tell a motivating story: most metabolic markers improve meaningfully on this class of medication, and seeing that improvement in data is a powerful reinforcement for the lifestyle changes that amplify the drug's effects

This guide covers the ten most clinically important biomarkers for anyone on a GLP-1 receptor agonist. For each, we explain what it is, why it is particularly relevant in this therapeutic context, what the reference ranges mean, what GLP-1 therapy typically does to it, and what you can do — nutritionally and through lifestyle — if your numbers are not where you want them. We also address three additional markers worth discussing with your provider, provide a practical testing timeline, and answer the questions patients are searching for most. For the companion guide on what labs to order before starting therapy, see: Labs Before Semaglutide: Complete GLP-1 Blood Work Guide.

Why Lab Monitoring Matters on GLP-1 Medications

There is a common misconception — sometimes inadvertently reinforced by prescribers — that lab monitoring is optional on GLP-1 therapy. Technically, for weight management (as opposed to diabetes management), that is true: no regulatory body mandates bloodwork as a condition of continuing semaglutide or tirzepatide.[1] However, optional is not the same as unnecessary. Several clinical realities make monitoring valuable:

• Baseline matters. Without pre-treatment labs, you have no reference point against which to measure improvement or detect early decline. Many patients starting GLP-1s have undiagnosed prediabetes, subclinical fatty liver disease, or existing micronutrient deficiencies — all of which directly affect how the medication performs and how the patient tolerates it.
• GLP-1s affect multiple organ systems simultaneously. The pancreas, liver, kidneys, gut, bone, and cardiovascular system are all in play. A change in any one system may show up in labs before it manifests as a symptom.
• Nutritional risk is real and underappreciated. A large US database study of 461,382 adults on GLP-1 receptor agonists found that 12.7% were diagnosed with a new nutritional deficiency within six months of starting treatment, rising to 22.4% by twelve months.[2] Vitamin D deficiency was the most common finding, followed by B12, iron, and other micronutrients.
• Monitoring drives better outcomes. Patients who see their biomarkers improve are more likely to sustain the lifestyle changes — dietary quality, physical activity, protein intake — that amplify GLP-1's effects. The data becomes a feedback mechanism, not just a safety check.

When to Test: A Practical Timeline

Before starting: Establish a full metabolic baseline. This is your reference point for everything that follows. See Labs Before Semaglutide for a detailed checklist.

3 months in: Early check-in for glycemic markers (HbA1c, fasting glucose), liver enzymes, and kidney function — especially if dose has been titrated upward.

Every 6 months: Full panel including lipids, nutritional markers (B12, Vitamin D), CBC, and inflammatory markers.

Annually: Thyroid function, bone-related markers, and any markers that have been consistently normal.

Most patients benefit from testing every three to six months during active treatment, with a comprehensive baseline panel before beginning therapy.[3] Patients with pre-existing diabetes, cardiovascular disease, or renal impairment will generally require more frequent monitoring, tailored to their specific clinical picture. Meto's Advanced Metabolic Lab Panel covers all ten biomarkers in this guide and 60+ additional markers in a single, streamlined order.

The 10 Biomarkers

Biomarker 01: HbA1c (Hemoglobin A1c)

Category: Glycemic Control

The primary measure of whether your GLP-1 medication is doing its most fundamental job

What it is: Hemoglobin A1c reflects the average concentration of glucose in the bloodstream over the preceding 90 to 120 days. When glucose attaches to haemoglobin — the protein inside red blood cells — it forms glycated haemoglobin. Because red blood cells have a lifespan of roughly three months, the HbA1c reading represents a rolling average that a single fasting glucose measurement cannot capture. For a deeper look at what HbA1c levels mean, including why it can be elevated in non-diabetic patients, see Meto's article on High A1C But Not Diabetic? Causes, Normal Ranges & What It Means.

Why it matters on GLP-1 therapy: GLP-1 receptor agonists work in part by stimulating glucose-dependent insulin secretion and suppressing glucagon release — two mechanisms that directly lower blood glucose. HbA1c is therefore the gold-standard endpoint in nearly every major GLP-1 clinical trial. The STEP 2 trial (semaglutide 2.4 mg in adults with type 2 diabetes and overweight) demonstrated a mean HbA1c reduction of 1.6 percentage points versus placebo.[4] Even in patients without diabetes, the STEP 1 trial found that 84 to 85 percent of participants with baseline prediabetes achieved normoglycaemia (HbA1c below 5.7%) after 68 weeks of semaglutide treatment.[5]

Clinical significance: Every 1% reduction in HbA1c is associated with approximately a 40% reduction in risk of diabetes-related complications, including retinopathy, nephropathy, and neuropathy.[6] Monitoring HbA1c every three to six months allows clinicians and patients to assess whether the medication is delivering its intended metabolic benefit.

Lifestyle lever: Dietary carbohydrate quality — not just quantity — is the primary nutritional driver of HbA1c. Ultra-processed carbohydrates, sugar-sweetened beverages, and refined starches should be minimised. Protein-forward meals that blunt postprandial glucose spikes, combined with resistance training (which improves skeletal muscle glucose uptake), create the strongest synergy with GLP-1 therapy. If HbA1c is not improving after three months at a stable dose, the conversation should include medication adherence, dietary patterns, and potential dose adjustment.

Biomarker 02: Fasting Blood Glucose

Category: Glycemic Control

The immediate snapshot that complements HbA1c's long view

What it is: Fasting blood glucose measures the concentration of glucose in the bloodstream after a minimum of eight hours without caloric intake. Unlike HbA1c, it captures a single moment in time — your metabolic state in the overnight fasted condition.

Why it matters on GLP-1 therapy: One of the more clinically reassuring features of GLP-1 receptor agonists is their glucose-dependent mechanism of action: they stimulate insulin secretion only when blood glucose is elevated. This means they possess a self-limiting, or "self-terminating," effect — once glucose falls to fasting levels, the insulinotropic signal attenuates.[7] In practical terms, GLP-1 monotherapy carries a low intrinsic risk of hypoglycaemia, which is not true of all glucose-lowering agents. That said, fasting glucose should still be monitored, particularly in patients who are also on insulin, sulfonylureas, or other agents that can independently cause hypoglycaemia.

Fasting glucose also captures phenomena HbA1c may obscure — specifically, the dawn phenomenon (a pre-waking glucose rise driven by cortisol and growth hormone) and fasting hyperglycaemia despite good postprandial control. For patients interested in understanding the relationship between stress hormones and glucose, see Meto's article on How Cortisol Affects Blood Sugar and Insulin Resistance.

Lifestyle lever: Evening meal composition has a disproportionate impact on fasting glucose — high-carbohydrate, high-glycaemic dinners elevate overnight glucose even in non-diabetic individuals. Prioritising protein and non-starchy vegetables at the evening meal, and avoiding late-night snacking, typically produces the most consistent fasting glucose improvement. Morning physical activity, even a 10–15 minute walk, can meaningfully lower fasting glucose by improving insulin sensitivity and drawing on muscle glycogen stores.

Biomarker 03: Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides)

Category: Cardiovascular Risk

Four numbers that collectively define your heart disease trajectory

What it is: A standard fasting lipid panel measures four components: total cholesterol (the sum of all lipoprotein particles), LDL cholesterol (the primary atherogenic fraction), HDL cholesterol (the protective fraction associated with reverse cholesterol transport), and triglycerides (a form of blood fat closely tied to dietary carbohydrate intake and insulin resistance). Non-HDL cholesterol — calculated as total cholesterol minus HDL — is increasingly used as a more comprehensive cardiovascular risk marker, as it captures all atherogenic lipoprotein particles. Meto's lab panel also includes ApoB and ApoA1, which provide superior cardiovascular risk stratification beyond the standard lipid panel.

Why it matters on GLP-1 therapy: The cardiovascular benefit of GLP-1 receptor agonists is well-established. The SUSTAIN-6 trial demonstrated significant reductions in major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes.[8] At the lipid level, weight loss generally improves the entire panel: LDL and total cholesterol decline, triglycerides fall (often dramatically, particularly in patients with prior hypertriglyceridaemia), and HDL typically rises.[9] However, these benefits are diet-dependent. A patient who continues to consume high quantities of refined carbohydrates and alcohol may not see expected triglyceride reductions despite substantial weight loss.

Lifestyle lever: Triglycerides are the most diet-responsive component of the lipid panel — reducing alcohol, refined carbohydrates, and fructose (including from fruit juices) can lower triglycerides substantially within six to eight weeks. LDL is more influenced by saturated fat intake, dietary cholesterol, and genetic factors. Omega-3 fatty acids (from oily fish or supplementation) have well-documented triglyceride-lowering effects.[10] Patients who fail to see expected lipid improvements on GLP-1 therapy should have a full dietary assessment before escalating pharmacological lipid management. For context on how insulin resistance intersects with lipid abnormalities, see Meto's article on Insulin Resistance: Signs, Tests & How to Reverse It Naturally.

Biomarker 04: Liver Enzymes (ALT & AST)

Category: Liver Health / Safety Monitoring

Critical for the large overlap between GLP-1 users and undiagnosed fatty liver disease

What they are: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are enzymes produced primarily within liver cells. When hepatocytes are damaged or inflamed, these enzymes are released into circulation, where they can be detected in a standard blood panel. ALT is more liver-specific; AST is found in muscle, heart, and other tissues as well, so elevated AST with normal ALT may warrant additional investigation. Meto's metabolic panel also measures GGT (gamma-glutamyl transferase), which adds further sensitivity for alcohol-related liver stress and bile duct involvement.

Why it matters on GLP-1 therapy: Non-alcoholic fatty liver disease (NAFLD) — now more precisely termed metabolic dysfunction-associated steatotic liver disease, or MASLD — affects an estimated 25% of the global adult population, with prevalence rising to 55–65% among individuals with type 2 diabetes.[11] Many GLP-1 candidates have subclinical or overt hepatic steatosis before starting therapy. GLP-1 receptor agonists are among the few pharmacological interventions that have demonstrated histological improvement in NAFLD/MASLD. Studies show maximum ALT reduction occurring around week 30 of semaglutide treatment, correlating with reductions in hepatic fat content.[12] Tracking liver enzymes therefore serves a dual purpose: it confirms therapeutic benefit in those with fatty liver, and it provides an early warning if any hepatic stress is occurring.

Lifestyle lever: Alcohol is hepatotoxic even at moderate consumption levels, and its impact is amplified in individuals with pre-existing hepatic steatosis. Reducing or eliminating alcohol is the single most impactful liver-specific lifestyle intervention. Ultra-processed food consumption, independent of caloric intake, is associated with NAFLD progression. Weight loss pace also matters: very rapid weight loss (particularly from crash dieting or extreme caloric restriction) can transiently worsen liver inflammation. Meto offers specialist care for Fatty Liver Disease as part of its comprehensive metabolic health service.

Biomarker 05: Kidney Function Panel (eGFR, Creatinine, UACR)

Category: Renal Safety Monitoring

Often overlooked but essential for long-term GLP-1 safety, especially in diabetic patients

What it is: The kidney function panel typically includes serum creatinine (a waste product of muscle metabolism), estimated glomerular filtration rate (eGFR, calculated from creatinine and patient demographics), and — particularly in diabetic patients — the urine albumin-to-creatinine ratio (UACR), which detects protein leakage into urine as an early marker of renal injury. Meto's lab panel includes BUN, creatinine, BUN/creatinine ratio, and osmolality for a comprehensive renal picture.

Why it matters on GLP-1 therapy: GLP-1 receptors are expressed in the kidney, and there is accumulating evidence that GLP-1 receptor agonists have direct renoprotective effects, particularly in the context of diabetic nephropathy. For diabetic patients, UACR may improve with treatment, suggesting a reduction in glomerular hypertension and inflammatory injury.[13] However, the gastrointestinal side effects of GLP-1 therapy — particularly nausea and vomiting during dose escalation — can cause clinically significant dehydration, which is a common precipitant of acute kidney injury (AKI). This is a documented safety concern in the literature, with case reports of AKI associated with semaglutide, primarily in the context of severe dehydration.[14] Additionally, GLP-1 agonists have been shown to suppress thirst (hypodipsia) in some patients, making voluntary dehydration a real risk that warrants proactive management.[15]

Lifestyle lever: Consistent hydration is the most directly actionable kidney-protective habit for GLP-1 users. Targeting a minimum of 2–2.5 litres of fluid daily, and actively tracking intake during periods of nausea or elevated ambient temperature, reduces dehydration risk substantially. A dietary sodium reduction supports blood pressure control, which is a key driver of renal disease progression. Patients with established chronic kidney disease should discuss dose selection with a nephrologist before initiating GLP-1 therapy.

Biomarker 06: Thyroid Function (TSH)

Category: Hormonal Health / Safety Monitoring

The most searched GLP-1 safety question — and one that deserves a nuanced answer

What it is: Thyroid-stimulating hormone (TSH) is secreted by the pituitary gland and regulates the thyroid's production of thyroxine (T4) and triiodothyronine (T3). TSH is the most sensitive screening marker for thyroid dysfunction: it rises when the thyroid is underperforming (hypothyroidism) and falls when it is overactive (hyperthyroidism). When TSH is abnormal, reflex testing of free T4 and, in some cases, free T3 and thyroid antibodies provides additional clinical detail. Meto provides specialist care for thyroid disorders as part of its Hormonal Health service.

Why it matters on GLP-1 therapy: The prescribing information for semaglutide (and other GLP-1 receptor agonists) includes a black box warning regarding thyroid C-cell tumours, based on findings in rodent models at supratherapeutic doses.[16] It is important to contextualise this appropriately: these tumours were observed in species that, unlike humans, express high levels of GLP-1 receptors in thyroid C cells. Epidemiological data in humans have not confirmed a causal relationship with medullary thyroid carcinoma or thyroid tumours at clinical doses.[17] Nevertheless, patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) are contraindicated for GLP-1 receptor agonist therapy, and baseline thyroid assessment is prudent.

Beyond the safety question, there is a more practical clinical reason to monitor TSH: hypothyroidism and GLP-1 side effects share significant symptom overlap. Fatigue, weight loss plateaux, cold intolerance, and constipation can all be attributable to either condition. Ruling out thyroid dysfunction before attributing these symptoms to the medication prevents missed diagnoses and unnecessary dose adjustments.

Lifestyle lever: Adequate iodine intake (from iodised salt, seafood, and dairy) supports thyroid hormone synthesis. Selenium, found in Brazil nuts and seafood, is a cofactor for thyroid hormone conversion. Patients on levothyroxine should be aware that significant weight loss can alter thyroid hormone distribution and may require dose re-evaluation — an additional reason to monitor TSH during active weight loss.

Biomarker 07: Complete Blood Count (CBC)

Category: Blood Health / Safety Monitoring

The broad screen that catches nutritional deficiencies before they become symptoms

What it is: The complete blood count measures red blood cells (including haemoglobin and haematocrit), white blood cells (including differential subtypes), and platelets. It is a broad, cost-effective screen that provides insight into immune function, oxygen-carrying capacity, and early nutritional compromise. Meto's panel includes the full CBC with differential, including band neutrophils, reactive and variant lymphocytes, MCV, MCH, MCHC, and RDW for comprehensive haematological assessment.

Why it matters on GLP-1 therapy: Reduced dietary intake — which can fall by 30 to 50 percent on GLP-1 medications — creates an aggregate micronutrient shortfall that manifests in the blood count before it produces overt symptoms.[18] Two patterns are particularly relevant:

• Iron deficiency anaemia: GLP-1 agonists reduce gastric acid secretion and slow gastric emptying, both of which impair iron absorption. Iron is absorbed preferentially in the duodenum in an acidic environment; alterations to this environment reduce bioavailability. The CBC will show a low haemoglobin, low MCV (mean corpuscular volume), and low haematocrit in iron deficiency anaemia. Meto's panel includes ferritin and serum iron for more granular assessment — see also the guide on UIBC Blood Test Normal Range: What High & Low Levels Mean for context on interpreting iron studies.
• Macrocytic changes: A high MCV (large red blood cells) with low haemoglobin points to B12 or folate deficiency — both of which impair DNA synthesis in rapidly dividing erythroid precursors, producing abnormally large, immature red cells (megaloblastic changes). This finding warrants confirmatory B12 and folate testing.

Lifestyle lever: Haem iron (from red meat, poultry, and seafood) is absorbed at two to three times the rate of non-haem iron (from plant sources). Consuming vitamin C-rich foods alongside non-haem iron sources significantly improves absorption. Calcium and tannins (from tea and coffee) competitively inhibit iron absorption and should be separated from iron-rich meals by at least two hours. For patients interested in optimising B-vitamin intake through food, Meto's guide to 12 Foods High in Vitamin B6 provides useful dietary guidance on B-vitamin food sources.

Biomarker 08  Vitamin B12

Category: Nutritional Status / Neurological Health

One of the most under-monitored risks of long-term GLP-1 therapy

What it is: Vitamin B12 (cobalamin) is an essential water-soluble vitamin involved in DNA synthesis, red blood cell formation, myelin sheath maintenance, and one-carbon metabolism. It is found almost exclusively in animal-derived foods. Absorption requires two co-factors produced in the stomach: intrinsic factor (secreted by parietal cells) and adequate gastric acid (to liberate protein-bound B12 from food). Deficiency can remain subclinical for years before producing irreversible neurological damage.

Why it matters on GLP-1 therapy: This is one of the most important nutritional monitoring priorities for GLP-1 patients, and the one most frequently overlooked. GLP-1 receptor agonists slow gastric emptying and reduce gastric acid secretion — the two processes most critical for B12 liberation and binding to intrinsic factor. The result is a progressive, dose-dependent decline in B12 levels over months to years.[19]

The scale of this problem is documented in clinical literature. In one study, participants on long-term GLP-1 therapy experienced an average 15% decline in serum B12 over 12 months, with approximately 20% falling below the normal range.[20] This risk is compounded in patients who are also on metformin — which independently reduces B12 absorption through a separate ileal mechanism — and in vegetarians and vegans, who may have had marginal B12 status at baseline.

The clinical stakes are high. B12 deficiency causes peripheral neuropathy (numbness, tingling, burning pain in extremities), subacute combined degeneration of the spinal cord (which can be permanent if untreated), megaloblastic anaemia, and cognitive impairment. These symptoms can be wrongly attributed to GLP-1 side effects or the ageing process, leading to dangerous diagnostic delay. Beyond B12, case reports have documented severe thiamine (B1) deficiency — including Wernicke encephalopathy — in GLP-1 users with prolonged vomiting or severely restricted intake, reinforcing the need for broad B-vitamin vigilance.[21]

Lifestyle lever: Animal proteins — meat, fish, eggs, and dairy — are the primary dietary sources of B12. Patients should be counselled to prioritise these at each meal, within their appetite constraints. Vegetarians and vegans require supplementation regardless of GLP-1 status, but the threshold for supplementation is lower in GLP-1 users given the absorption impairment. For supplementation, methylcobalamin or adenosylcobalamin forms are preferable to cyanocobalamin in patients with absorption issues. High-dose sublingual or intramuscular B12 may be warranted in patients with confirmed deficiency or significantly reduced gastric function.

Biomarker 09  Vitamin D & Calcium

Category: Bone Health / Metabolic Function

The silent risk of rapid weight loss — bone density can fall even as metabolic markers improve

What they are: 25-hydroxyvitamin D (25-OH-D) is the primary circulating form of vitamin D and the most accurate marker of vitamin D status. Serum calcium reflects the concentration of this mineral in blood, though it is tightly regulated by parathyroid hormone (PTH) and does not decline easily — meaning serum calcium can appear normal even when bone stores are being depleted. A more sensitive assessment of calcium adequacy includes PTH levels and, when indicated, bone density scanning (DEXA).

Why they matter on GLP-1 therapy: Vitamin D deficiency was the most prevalent nutritional deficiency identified in GLP-1 users in the large database study referenced earlier, with incidence rising from 7.5% at six months to 13.6% at twelve months.[2] There are two intersecting mechanisms: first, vitamin D is fat-soluble and stored in adipose tissue; as fat mass is lost during GLP-1 therapy, vitamin D is released from storage, which can temporarily mask a developing deficiency. Second, if total caloric intake falls substantially (as is common on GLP-1s), dietary calcium and vitamin D intake may fall well below requirements.

The bone health implications are clinically significant. Rapid weight loss — of any cause — is associated with decreased bone mineral density (BMD). A clinical trial involving postmenopausal women on GLP-1 agonists documented a 1–2% reduction in BMD over twelve months of treatment.[22] This may seem modest, but it is clinically meaningful in patients who already have osteopenia, and it represents a silent risk that is completely preventable with adequate monitoring and supplementation.

Lifestyle lever: Resistance training is the most potent non-pharmacological intervention for preserving bone density during weight loss — it applies mechanical load that stimulates osteoblast activity. This is one of several reasons why resistance exercise is strongly recommended alongside GLP-1 therapy. Dietary calcium from dairy, fortified plant milks, canned fish with bones, and leafy greens provides a food-first foundation. Most GLP-1 patients with restricted caloric intake will benefit from supplemental vitamin D3 (typically 2,000–4,000 IU daily) and calcium supplementation, ideally in split doses to optimise absorption. For lifestyle context, see Meto's guide on GLP-1 Medications & Lifestyle: Balancing Medication, Nutrition, and Habits.

Biomarker 10  hsCRP (High-Sensitivity C-Reactive Protein)

Category: Systemic Inflammation / Cardiovascular Risk

The biomarker that captures the full metabolic dividend of GLP-1 therapy

What it is: High-sensitivity C-reactive protein (hsCRP) is an acute-phase protein produced by the liver in response to interleukin-6 and other inflammatory cytokines. In the context of metabolic health, chronically elevated hsCRP reflects the low-grade systemic inflammation that characterises obesity, insulin resistance, and type 2 diabetes — sometimes called "metaflammation." The high-sensitivity assay (as opposed to the standard CRP test used in acute infection) can detect elevations in the 1–10 mg/L range that are clinically relevant to cardiovascular risk stratification.

Why it matters on GLP-1 therapy: Systemic inflammation is both a cause and a consequence of metabolic dysfunction. Adipose tissue — particularly visceral fat — actively secretes pro-inflammatory cytokines, creating a self-perpetuating inflammatory environment that drives insulin resistance, endothelial dysfunction, and atherosclerotic progression. (For more on the role of visceral fat in metabolic disease, see Meto's article on How to Avoid High Visceral Fat.) As GLP-1 therapy reduces fat mass, hsCRP typically falls — reflecting a genuine reduction in inflammatory burden, not merely weight loss.[23] This means hsCRP improvement represents a cardiovascular risk reduction that is mechanistically distinct from, and additive to, the lipid and blood pressure improvements also seen with GLP-1 therapy.

hsCRP also serves as a practical motivational tool. It responds to lifestyle inputs — sleep quality, dietary pattern, physical activity — within weeks, giving patients near-real-time feedback on their metabolic trajectory in a way that HbA1c (which reflects a three-month average) cannot.

Lifestyle lever: The Mediterranean dietary pattern — characterised by high olive oil intake, abundant vegetables, legumes, whole grains, oily fish, and moderate polyphenol-rich foods — is the most evidence-backed anti-inflammatory dietary approach.[24] Sleep quality is an underappreciated driver: even one week of sleep restriction significantly elevates hsCRP and other inflammatory markers. For more on how sleep affects metabolic health, see Meto's article on How Sleep Deprivation Affects Metabolism. Aerobic exercise at moderate intensity (zone 2 training) produces consistent anti-inflammatory effects over four to eight weeks.

3 Additional Biomarkers Worth Discussing With Your Provider

The ten markers above represent the core monitoring panel for GLP-1 patients. The following three offer additional clinical insight for patients who want a more complete metabolic picture, or who have specific risk factors that make them particularly relevant. All three are included in Meto's Advanced Metabolic Lab Panel.

Fasting Insulin and HOMA-IR

HbA1c and fasting glucose measure the glucose side of the metabolic equation. Fasting insulin and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) measure the insulin side — specifically, how hard the pancreas is working to maintain glucose control. A patient with a "normal" fasting glucose of 98 mg/dL and a fasting insulin of 25 µIU/mL has significant insulin resistance not captured by glucose alone. HOMA-IR, calculated as (fasting glucose × fasting insulin) / 405, provides a composite index that tracks improvement in insulin sensitivity over the course of GLP-1 therapy. Many patients see dramatic HOMA-IR reductions within three to six months, even before meaningful weight loss — a sign that GLP-1 is improving pancreatic and hepatic insulin dynamics directly. For a comprehensive overview, see Meto's guide on Insulin Resistance: Signs, Tests & How to Reverse It Naturally.

Uric Acid

Rapid weight loss — from any cause, including GLP-1 therapy — can transiently elevate serum uric acid through two mechanisms: increased purine load from cell turnover, and reduced renal urate excretion during early caloric restriction. For patients with a history of gout or elevated uric acid at baseline, this is a relevant monitoring priority, particularly in the first three to six months of therapy.[25] Adequate hydration, low fructose intake, and reduced alcohol consumption are the primary uric acid-lowering lifestyle interventions. Meto's metabolic panel includes uric acid as a standard marker.

Pancreatic Enzymes (Amylase and Lipase)

GLP-1 receptor agonists slow gastric emptying significantly — food may remain in the stomach for four to six hours versus the normal two to four hours.[26] In susceptible individuals, this prolonged gastric distension, combined with potential increases in pancreatic secretion, creates conditions that can precipitate pancreatitis. The overall risk is debated in the literature — large observational studies have not confirmed a causal association — but patients with unexplained, persistent upper abdominal pain radiating to the back should have amylase and lipase tested promptly, and GLP-1 therapy should be paused pending investigation.[27] This is not a routine monitoring marker but one that should be measured immediately if relevant symptoms arise. Both amylase and lipase are included in Meto's Advanced Metabolic Panel.

What to Do With Your Results: A Practical Framework

A lab result without a decision-making framework is just a number. Here is how to use your biomarker data:

If all markers are within range:

Document your baseline values, schedule your next panel at three to six months, and use the data to reinforce the lifestyle behaviours that are working. Your numbers are evidence — treat them as such. Log them in your Meto dashboard to track trends over time.

If one marker is borderline:

Identify the specific lifestyle lever for that marker (dietary quality, hydration, specific micronutrient intake, sleep, exercise) and implement it deliberately for eight to twelve weeks before retesting. Most borderline results respond to targeted nutritional and lifestyle interventions without requiring pharmacological adjustment.

If a marker is significantly abnormal:

Contact your healthcare provider. Do not self-adjust GLP-1 dosing, discontinue the medication, or start aggressive supplementation without clinical guidance. Results more than 3x above the upper limit of normal for liver enzymes, eGFR below 30, B12 below 150 pg/mL, or persistent hypoglycaemia all warrant timely provider contact. Meto's care team is available for results review — book a follow-up appointment here.

If you are experiencing symptoms between scheduled tests:

Do not wait for your next scheduled panel. Fatigue, numbness or tingling, persistent nausea beyond the titration period, upper abdominal pain, unusual bruising, or significant hair loss are all indications for an off-cycle blood test.

Biomarker Quick Reference: Lifestyle Levers and Alert Thresholds

How Often Should GLP-1 Patients Get Blood Work?

This is one of the most frequently searched questions among GLP-1 users. The answer depends on patient-specific factors, but here is a practical framework that aligns with American Diabetes Association and Obesity Medicine Association guidance. For a detailed pre-therapy checklist, see Meto's companion guide: Labs Before Semaglutide: Complete GLP-1 Blood Work Guide (2026).

• Before starting therapy: Comprehensive baseline panel — HbA1c, fasting glucose, full lipid panel, ALT/AST, eGFR/creatinine, TSH, CBC, B12, vitamin D, hsCRP, and fasting insulin. This is non-negotiable for evidence-based GLP-1 management.
• At 3 months: Glycaemic markers (HbA1c, fasting glucose), liver enzymes, kidney function. This coincides with the end of the typical dose titration period and a meaningful weight loss interval.
• Every 6 months (ongoing): Full panel including lipids, B12, vitamin D, CBC, and hsCRP. Adjust timing for any marker that was abnormal at the previous visit.
• Annually: Thyroid function, fasting insulin/HOMA-IR, and any markers consistently within range. Bone density assessment (DEXA) is appropriate at baseline and every one to two years for women over 50 and any patient with prior low bone density

Patients with type 2 diabetes, cardiovascular disease, chronic kidney disease, or established nutritional deficiencies will require more frequent monitoring as clinically directed. Meto's Advanced Metabolic Lab Panel provides all of the above in one streamlined order, with results reviewed by your care team and integrated into your Meto protocol dashboard.

Meto's Perspective on GLP-1 Biomarker Monitoring

Purpose-built lab panels for patients who want to do this right

At Meto, we work from a straightforward clinical premise: the full value of GLP-1 therapy cannot be realised without systematic tracking of the physiological changes it produces. Weight on a scale is one signal. The ten biomarkers in this guide are ten more — and collectively, they tell a more complete, more actionable story than any single number can.

What we observe consistently in clinical practice is that unmonitored GLP-1 therapy creates avoidable gaps: patients who plateau without understanding why; fatigue attributed to the medication when it is actually B12 or iron deficiency; bone density changes that go undetected until a fracture occurs; lipid profiles that do not improve because no one addressed dietary quality alongside the prescription. These are not inevitable outcomes — they are the predictable consequences of insufficient data.

That is why Meto has built a purpose-designed Advanced Metabolic Lab Panel that consolidates all the core biomarkers in this guide — and over 60 additional markers — into a single, streamlined order. No navigating a fragmented lab menu. No wondering which tests your provider may have missed. One comprehensive panel, reviewed in the context of your full protocol, before and throughout your GLP-1 journey.

Our panel includes: HbA1c, fasting glucose, fasting insulin, HOMA-IR, C-peptide, comprehensive lipid panel (including ApoB, ApoA1, and Lp(a)), ALT, AST, GGT, eGFR, creatinine, BUN, TSH, CBC with differential, vitamin B12, vitamin D (25-OH-D), serum calcium, magnesium (serum and RBC), ferritin, serum iron, uric acid, hsCRP, homocysteine, amylase, lipase, cortisol, and creatine kinase.

Your results integrate directly into your Meto dashboard, where your care team reviews them, adjusts your care plan, and ensures every clinical decision is informed by your most current data. All testing is conducted through CLIA-certified laboratory partners, with results delivered in 3–5 business days.

Meto offers specialist care across Weight Management, Type 2 Diabetes, Hormonal Health, Metabolic Syndrome, Fatty Liver Disease, and Longevity & Preventive Care — all areas directly relevant to patients on GLP-1 therapy.

Order Your Comprehensive Metabolic Panel

All 10 core GLP-1 biomarkers + 60 additional markers. One order. Results reviewed by your Meto care team in 3–5 business days.

Order at meto.co/labs  →

Frequently Asked Questions

Do I need blood work before starting Ozempic or Wegovy?

Technically, no blood work is legally required before a prescription can be written. However, starting GLP-1 therapy without baseline labs is like beginning a road trip without knowing where you started — you cannot meaningfully measure progress or detect early problems. A baseline panel including HbA1c, fasting glucose, lipids, liver enzymes, kidney function, TSH, B12, and vitamin D provides a comprehensive metabolic reference point. Most patients find that their baseline results also reveal conditions they were unaware of — prediabetes, fatty liver, or vitamin D deficiency — that directly shape how they approach the medication and their lifestyle alongside it. See Meto's full checklist in Labs Before Semaglutide: Complete GLP-1 Blood Work Guide (2026).

What blood tests should I get while on Wegovy or semaglutide?

The ten markers described in this guide represent the core monitoring panel. At minimum, every GLP-1 patient should track HbA1c and fasting glucose (glycaemic control), a full lipid panel (cardiovascular risk), ALT and AST (liver safety), eGFR and creatinine (kidney safety), B12 (neurological and haematological safety), and vitamin D (bone health). hsCRP and TSH add additional clinical value and should be included at least annually. Meto's Advanced Metabolic Lab Panel covers all of these in a single order.

Can GLP-1 medications cause vitamin deficiencies?

Yes — and this is more common than most patients are told. The reduced caloric intake typical on GLP-1 therapy (often 30 to 50 percent below baseline), combined with altered gastric emptying and reduced gastric acid secretion, creates both an intake deficiency and an absorption deficiency for multiple micronutrients.[18] B12, vitamin D, iron, calcium, folate, and zinc are the most clinically relevant. A large study of over 461,000 GLP-1 users found that more than one in five developed a diagnosable nutritional deficiency within twelve months of starting therapy.[2] Proactive supplementation — particularly of B12, vitamin D, and a comprehensive multivitamin — along with regular lab monitoring, is the most effective mitigation strategy.

Why am I so tired on semaglutide — is it a lab issue?

Fatigue is one of the most commonly reported non-gastrointestinal side effects of GLP-1 therapy, and it has multiple potential causes. Reduced caloric intake can cause a transient energy deficit early in therapy. However, fatigue that persists or worsens after the first four to six weeks warrants investigation. The most common lab-based causes are B12 deficiency (affecting neurological energy metabolism), iron deficiency anaemia (reducing oxygen-carrying capacity), vitamin D deficiency (associated with musculoskeletal fatigue), and hypothyroidism (which should be ruled out at baseline). A targeted blood panel — B12, CBC with ferritin, vitamin D, and TSH — will identify or exclude these causes efficiently. Book a follow-up with your Meto provider if fatigue persists beyond the initial titration period.

What does a good HbA1c trajectory look like after starting semaglutide?

In patients with prediabetes or type 2 diabetes, a meaningful HbA1c reduction typically becomes visible at the three-month mark and continues through 6 to 12 months. In STEP 2 trial data, the average HbA1c reduction from baseline was 1.6 percentage points over 68 weeks.[4] In patients with prediabetes, 84 to 85% achieved normoglycaemia within the same timeframe.[5] If HbA1c is not meaningfully declining after three months at a therapeutic dose, review dietary carbohydrate quality, meal timing, physical activity, sleep, and possible dose escalation. For context on interpreting your A1c result, see Meto's guide on High A1C But Not Diabetic? Causes, Normal Ranges & What It Means.

Does Ozempic affect my kidneys or liver?

In most patients, the effect on both organs is beneficial. For the liver, GLP-1 receptor agonists have demonstrated reductions in hepatic fat content and improvements in liver enzyme levels, particularly in patients with NAFLD/MASLD.[12] For the kidneys, there is evidence of direct renoprotective effects — particularly reducing urine albumin — in diabetic patients.[13] The primary kidney safety concern is indirect: dehydration from nausea and vomiting during dose escalation can precipitate acute kidney injury in susceptible patients.[14] Staying adequately hydrated and communicating persistent gastrointestinal symptoms to your provider mitigates this risk substantially. Meto's care team can help you navigate both monitoring and management — get started here.